Sponsored Content for Riccardo Canevari

Radiopharm Theranostics has banked US$2 million from American medical giant Lantheus for the sale of two preclinical antibody assets that target and help to diagnose aggressive cancers. Lantheus is also set to tip in a further US$5 million via a placement at 5c a share – a 42 per cent premium to today's price – with an option for another US$5 million investment within six months.

Radiopharm Theranostics has been given the nod of approval by the United States Food and Drug Authority to use its brain cancer-fighting technology in late-stage trials, with a first patient expected to be dosed later this year. The company's “F18-Pivalate” agent is designed to seek out and define a fatty acid that is overexpressed in brain tumours, but not in normal cells.

Radiopharm Theranostics has kicked off the first phase of clinical trials testing its “RAD 204” treatment aimed at beating the most common type of lung cancer – non-small cell lung cancer (NSCLC) – after dosing its first patient in New South Wales. The first in-human trial at the Wollongong Hospital has been designed to assess the safety and tolerability of the company's innovative radiopharmaceutical therapy.

Radiopharm Theranostics' stock rocketed up more than 35 per cent this morning after the cancer-fighting firm secured commitments from leading international and Australian institutional investors to raise $70 million at a premium to its most recent share price. The funds will be used to advance the company's clinical programs for the diagnosis and treatment of cancer through its innovative radiopharmaceutical products.

Radiopharm Theranostics says a new six-patient study shows its terbium-based treatment has superior potential to tackle prostate cancer than lutetium following a head-to-head assessment of the rare earths metals in its therapies. Management says the results from tests on patients with metastatic “castrate-resistant” cancer vindicate its development of next-generation, terbium-based radiotherapies for the treatment of the often deadly condition and other advanced cancers.

Radiopharm Theranostics says it has dosed its first pancreatic cancer patient in the initial phase of a study aimed at providing doctors with an enhanced screening process for the lethal and aggressive disease. The clinical trial is for the company's patented “RAD301” radiopharmaceutical technology that is designed to detect lesions in patients with pancreatic ductal adenocarcinoma and create better health outcomes.

Radiopharm Theranostics is poised to open a second site for conducting human trials of its RAD 204 treatment for advanced non-small cell lung cancer (NSCLC) having received the green light from Perth's Hollywood Private Hospital's Human Research Ethics Committee. The approval follows its successful Brisbane site initiation visit at Princess Alexandra Hospital prior to trials which are slated to begin as soon as next week.

Radiopharm Theranostics has stepped closer to kicking off what it says could be a “game-changing” trial for patients with non-small cell lung cancer (NSCLC) after a successful initiation site visit to Brisbane's Princess Alexandra Hospital. The visit was made ahead of the trial that will evaluate the safety and efficacy of the company's treatment for advanced NSCLC – the most common type of lung cancer.

Pancreatic cancer patients have been delivered fresh hope following the United States Food and Drug Administration's decision to clear the way for Radiopharm Theranostics to run clinical trials to address an area of “unmet need”. The imaging trials are designed to detect lesions in patients with pancreatic ductal adenocarcinoma and the first patient is expected to receive dosage by the end of this month.

The Human Research Ethics Committee has given Radiopharm Theranostics its stamp of approval to begin first-in-human phase-one dose escalation trials in Australia on patients living with non-small cell lung cancer. The company says the vital approval will allow it to pursue greater hope for patients dealing with a devastating condition that currently has a “poor prognosis” in terms of life expectancy.

Radiopharm Theranostics has negotiated an expanded agreement with TerThera for the supply of the terbium-161 isotope to continue its fight against prostate cancer. The crucial isotope will be joined with a proprietary monoclonal antibody to form “RAD 402”, a radiotherapeutic being developed to target KLK3, a clinical cancer biomarker. Radiopharm says it could become the first KLK-based theranostic option for patients with advanced prostate cancer.

A positive meeting with the United States Food and Drug Administration has boosted Radiopharm Theranostics' approval prospects for an investigational new drug clinical trial for its brain cancer treatment. The company's F18-Pivalate is a novel radiotracer that combines a molecule and a radioisotope for the detection, characterisation and monitoring of brain metastases and glioblastoma – an aggressive form of brain cancer.

A pancreatic cancer treatment developed by ASX-listed Radiopharm Theranostics has been granted crucial orphan drug designation by the United States Food and Drug Administration just weeks before clinical trials begin. The approval is for the company's patented RAD301 integrin technology that aims to assist with the imaging and treatment of patients with pancreatic ductal adenocarcinoma.

ASX-listed biotech Radiopharm Theranostics has secured the supply of a valuable isotope that will enable the company to soon kick off a human trial of a treatment designed to tackle brain cancer. Management says the isotope, Therbium-161, boasts great promise in helping to expand treatment options for patients living with cancer – but it is in short supply.

Australians suffering hard-to-beat cancers are set to be the first to benefit from trials of new treatments conducted as part of a two-year partnership between Radiopharm Theranostics and GenesisCare. Tumours in the brain, lung and prostate will be targeted in three first-phase clinical trials in Australia, which will be aimed at studying the safety and tolerability of Radiopharm's novel radiopharmaceutical treatments.

Medical technology company Radiopharm Theranostics has entered into a binding agreement to acquire Pharma15 Corporation – a US-based company focused on therapeutic radiopharmaceuticals to treat prostate cancer. Pharma15 is developing products that aim to overcome resistance to prostate-specific membrane antigen targeting cancer therapies currently available or in late-stage development.

Radiopharm Theranostics is aiming for the Big Apple. The Melbourne-based medical technology company that specialises in developing radiopharmaceutical products to diagnose and treat cancers is applying to list on the Nasdaq. If successful, the company expects to be given the ticker RADX. The Nasdaq listing will complement the existing primary listing of its ordinary shares with the ticker RAD on the ASX.

Radiopharm Theranostics has appointed Rama Abu Shmeis as Senior Vice President Chemistry, Manufacturing and Controls, or “CMC” as the latest in a line of top-shelf appointments. The ASX-listed cancer fighter says Dr Shmeis brings a 23-year record of achievements in leading strategic, operational and scientific aspects of CMC development and manufacturing that also covers a wide variety of dose forms, products and technologies.

Radiopharm Theranostics has been given the keys to the United States outpatient clinics to begin imaging trials of patients with pancreatic cancer after receiving the tick of approval from the US Food and Drug Administration for its cancer-seeking peptide.The USFDA has granted Radiopharm investigational new drug approval which will allow the company to test its patented RAD301 integrin technology in the real world.

ASX-listed biotech Radiopharm Theranostics has been buoyed by positive data generated by one of the company's products in imaging an aggressive and deadly type of breast cancer, with company management describing the results as “outstanding”. The data relates to Radiopharm's RAD201 treatment and is included in an article in the latest edition of a prestigious European medical journal.

Medical technology company Radiopharm Theranostics says new data released by Imperial College London from a phase 2 trial it conducted on the company's F-18 Pivalate radiotracer adds weight to its belief the product can be used to monitor brain cancer – a potentially huge market because up to 40 per cent of cancer patients develop metastatic cancer in the brain.

Melbourne-based Radiopharm Theranostics has reached an agreement with Australia's Nuclear Science and Technology Organisation for the supply of a vital ingredient required for its fight against cancer. The ingredient is a short-lived radioactive isotope called non-carrier-added lutetium-177, or Lu-177, that has promising properties for treating certain cancers. Lu-177 will be used in an upcoming trial of patients with lung cancer.

ASX-listed medical technology specialist Radiopharm Theranostics has strengthened the supply chain for a critical ingredient in its cancer-fighting treatments by inking a 10-year deal with an American supplier. The agreement with Wisconsin-based NorthStar Medical Radioisotopes is for Actinium-225, also known as Ac-225, which is a radioactive medical isotope used in a wide range of cancer treatments.

Medical technology specialist Radiopharm Theranostics is gearing up to approach the powerful US Federal Food and Drug Administration, or “FDA” to get its cancer treatment known as “Pivalate” to market after successfully concluding a phase II clinical trial in the UK. The trial indicated that Pivalate can detect and monitor secondary brain tumours regardless of the origin of the primary cancer.

Radiopharm Theranostics has linked with US-based nuclear technology specialist SHINE Technologies to ensure supply of a key component of the Melbourne-based company's radiopharmaceutical products pipeline. SHINE has developed a proprietary isotope production process and the two companies have entered into a clinical supply agreement for the supply of Lu-177 – an important cancer-fighting isotope used in multiple programs across Radiopharm's portfolio.

A cancer treatment licenced by ASX-listed Radiopharm Theranostics has been recognised with another endorsement from the US Food and Drug Administration after receiving rare paediatric disease designation. The approval is for a tumour-killing antibody known as DUNP19 used to treat osteosarcoma — a type of bone cancer that primarily affects children, adolescents and young adults.

Radiopharm Theranostics has partnered with a US research centre to launch Radiopharm Ventures — a joint venture that aims to develop radiopharmaceutical therapeutic products to help in the fight against cancer. The new company has been created in partnership with the University of Texas MD Anderson Cancer Centre and will initially focus on developing at least four therapeutic products based on the centre's intellectual property.

A bone cancer treatment technology licenced by ASX-listed Radiopharm Theranostics has been granted orphan drug designation by the United States Food and Drug Administration. The approval is for a tumour-killing antibody known as DUNP19 that targets LRRC15, a substance produced by aggressive cancer cells in the surrounding micro-environment, but not healthy normal tissue.

Cancer fighter Radiopharm Theranostics has inked a deal for the supply of a key component needed to develop its pipeline of radiopharmaceutical therapy products. Radiopharm says its agreement with Israeli company Isotopia Molecular Imaging for a high-quality radioisotope called Lutetium-177 will enable it to accelerate its diverse clinical pipeline of radiopharmaceutical products slated for the multi-billion-dollar oncology market.

ASX-listed Radiopharm Theranostics is moving quickly to add another cancer-fighting weapon to its diagnostic armoury after penning a sub-licensing agreement for a promising radiopharmaceutical agent with a US company. The Melbourne-based biotech company believes the agent can target several tumour types, including gynaecological cancers however the company is focusing first on its possibilities for detecting and treatment of aggressive brain tumours.

Cancer fighting biotech Radiopharm Theranostics has licensed another tumour killing antibody, known as DUNP19, from its US development partners, adding to the company's clinical development pipeline of radiotherapy cancer treatments. The antibody is unique in its dual action in killing both the cancerous tumour and micro-environment cells that make up most of the mass of a solid tumour.

Radiopharm has agreed on commercial terms to commence its first phase of lung cancer trials in Australia with renowned global oncology provider GenesisCare. The program aims to start testing Radiopharm's proprietary nanobodies, part of its Nano-mAbs platform, by targeting non-small cell lung cancer, the most common type of the disease. The project is scheduled to be completed within 18 months.

Cancer fighting biotech, Radiopharm Theranostics has gained access to a rare medical isotope from a Bill Gates start-up to accelerate the development of its pipeline of cancer treatment therapies. The company says “actinium-225” is a radioactive isotype that can be attached to a targeting antibody that will then selectively target and destroy cancerous tissue.